nafamostat has been researched along with resiquimod in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Anthony, DC; Dunstan, IK; Strekalova, T; Weglinski, CM; Yates, AG; Ying, Y | 1 |
2 other study(ies) available for nafamostat and resiquimod
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness.
Topics: Animals; Benzamidines; COVID-19; COVID-19 Drug Treatment; Guanidines; Illness Behavior; Imidazoles; Inflammation; Male; Mice; Serine Endopeptidases; Serine Proteinase Inhibitors; Toll-Like Receptor 7; Virus Diseases | 2022 |